Lithium carbonate is a treatment of choice for bipolar depression. 1 It has been investigated as an immunoprotective agent 2 with poor results. More recently, in animal models, it has been shown to protect against HIV-associated encephalitis. 3 Major depression affects about 36% of the HIVinfected population, with a wide variability (4%-45%), and its management is crucial to obtain positive results with highly active antiretroviral therapy (HAART). 4 However, a recent review 5 did not include lithium salts in the analysis of treatments for depression and anxiety in HIV-infected patients and of drug interactions. Lithium carbonate does not appear even on HIV drug-interaction Web sites.
Among our 968 HIV-infected outpatients on HAART, 3 were on lithium carbonate therapy. One is on concomitant triple nucleoside antiretroviral therapy (ART) and has no problems, whereas when the others switched to ritonavir/atazanavir-based regimens, their depression worsened, and their lithium levels dropped.
A 46-year-old man, an intravenous drug addict between 1971 and 1999, was found to be HIV-infected in jail in 1990. After failure with Combivir + indinavir and intolerance to efavirenz (hallucination and worsening of depression), he was switched to Combivir + tenofovir + Kaletra. In May 2001, he was newly jailed for an old crime and treatment was interrupted. In prison, his depression worsened, and he started lithium carbonate therapy. He was released in September 2004 on maintenance lithium therapy (450 mg twice daily; mean plasma level, 1.47 mmol/L), and in October 2004, he started a new HAART regimen, tenofovir + lamivudine + 300 mg atazanavir + 100 mg ritonavir once daily. After 3 weeks, he complained of anxiety, with frequent tremors and depressed mood, which had temporarily resolved in the previous months. In November 2004, his lithium level had dropped to 0.09 mmol/L (normal range, 0.5-1.5 mmol/L). Urine lithium levels, also tested, were proportional to blood levels.
A 35-year-old heterosexual woman, HIV known since 1999, started HAART in June 2000 with zidovudine + lamivudine + 800 mg indinavir + 100 mg ritonavir twice daily, in August switched for gastrointestinal intolerance to stavudine + lamivudine + 100 mg saquinavir + 100 mg ritonavir twice daily. Since 1999, she also received lorazepam and alprazolam for depression. In January 2001, she asked for simplification for adherence problems. She switched to Trizivir, but after 1 month, she underwent CD4-driven structured treatment interruption, which lasted until September 2005. Mainly because of general symptoms (malaise, fatigue, frequent low fever), with a CD4 count of 290/mm 3 and 67 000 copies/mL HIV RNA, she started Kivexa + 300 mg atazanavir + 100 mg ritonavir once daily. Since July 2005, she has been on stable lithium maintenance (450 mg twice daily) for severe bipolar depression (having discontinued the former therapy); 2 weeks after starting the new regimen, she complained about instability, with compulsions, panic, and deep depression. Despite doubling the dose, her plasma levels dropped from 1.23 to 0.13 mmol/L in December 2005, and it was decided to discontinue HAART. While taking therapies, the patient has always been highly adherent, and all discontinuations followed discussion with the clinician.
Despite the anecdotal character of this report, we feel that lithium levels should be monitored when boosted protease inhibitors are concomitantly assumed.
